Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development

Science Translational Medicine

Volumn 1, Issue 2, 2009, Pages

  Takala, Shannon L ^a   Coulibaly, Drissa ^b   Thera, Mahamadou A ^b   Batchelor, Adrian H ^c,f   Cummings, Michael P ^d   Escalante, Ananias A ^e   Ouattara, Amed ^a,b   Traoré, Karim ^b   Niangaly, Amadou ^b   Djimdé, Abdoulaye A ^b   Doumbo, Ogobara K ^b   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF BAMAKO   (Mali)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d Bldg 142   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN;

ARTICLE; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MALARIA FALCIPARUM; MALI; PLASMODIUM FALCIPARUM; RISK FACTOR;

ANTIGENS, PROTOZOAN; HUMANS; LONGITUDINAL STUDIES; MALARIA VACCINES; MALARIA, FALCIPARUM; MALI; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 76749133362     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000257     Document Type: Article

References (55)

1. A. A. Escalante, A. A. Lal, F. J. Ayala, Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 149, 189-202 (1998).
2. S. L. Takala, C. V. Plowe, Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming "vaccine resistant malaria ". Parasite Immunol. 31, 560-573 (2009).
3. M. Moran, J. Guzman, A. Ropars, M. Jorgensen, A. McDonald, S. Potter, H. Haile-Selassie, The Malaria Product Pipeline: Planning for the Future (The George Institute of International Health, London, 2007); www.thegeorgeinstitute. org/shadomx/apps/fms/fmsdownload.cfm?file-uuid=1ABDE79C-DA73-20B3-D6E1- F7AF25011EC9&siteName=iih [accessed July 2009].
4. M. Roestenberg, E. Remarque, E. de Jonge, R. Hermsen, H. Blythman, O. Leroy, E. Imoukhuede, S. Jepsen, O. Ofori-Anyinam, B. Faber, C. H. Kocken, M. Arnold, V. Walraven, K. Teelen, W. Roeffen, Q. de Mast, W. R. Ballou, J. Cohen, M. C. Dubois, S. Ascarateil, A. van der Ven, A. Thomas, R. Sauerwein, Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3, e3960 (2008).
5. I. Sagara, A. Dicko, R. D. Ellis, M. P. Fay, S. I. Diawara, M. H. Assadou, M. S. Sissoko, M. Kone, A. I. Diallo, R. Saye, M. A. Guindo, O. Kante, M. B. Niambele, K. Miura, G. E. Mullen, M. Pierce, L. B. Martin, A. Dolo, D. A. Diallo, O. K. Doumbo, L. H. Miller, A. Saul, A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27, 3090-3098 (2009).
6. M. A. Thera, O. K. Doumbo, D. Coulibaly, D. A. Diallo, A. K. Kone, A. B. Guindo, K. Traore, A. Dicko, I. Sagara, M. S. Sissoko, M. Baby, M. Sissoko, I. Diarra, A. Niangaly, A. Dolo, M. Daou, S. I. Diawara, D. G. Heppner, V. A. Stewart, E. Angov, E. S. Bergmann-Leitner, D. E. Lanar, S. Dutta, L. Soisson, C. L. Diggs, A. Leach, A. Owusu, M. C. Dubois, J. Cohen, J. N. Nixon, A. Gregson, S. L. Takala, K. E. Lyke, C. V. Plowe, Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial. PLoS One 3, e1465 (2008).
7. A. N. Hodder, P. E. Crewther, M. L. Matthew, G. E. Reid, R. L. Moritz, R. J. Simpson, R. F. Anders, The disulfide bond structure of Plasmodium apical membrane antigen-1. J. Biol. Chem. 271, 29446-29452 (1996).
8. A. Cortés, M. Mellombo, I. Mueller, A. Benet, J. C. Reeder, R. F. Anders, Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect. Immun. 71, 1416-1426 (2003).
9. A. A. Escalante, H. M. Grebert, S. C. Chaiyaroj, M. Magris, S. Biswas, B. L. Nahlen, A. A. Lal, Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol. Biochem. Parasitol. 113, 279-287 (2001).
10. S. D. Polley, D. J. Conway, Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158, 1505-1512 (2001).
11. T. Bai, M. Becker, A. Gupta, P. Strike, V. J. Murphy, R. F. Anders, A. H. Batchelor, Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc. Natl. Acad. Sci. U.S.A. 102, 12736-12741 (2005).
12. C. R. Collins, C. Withers-Martinez, F. Hackett, M. J. Blackman, An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog. 5, e1000273 (2009).
13. S. Dutta, S. Y. Lee, A. H. Batchelor, D. E. Lanar, Structural basis of antigenic escape of a malaria vaccine candidate. Proc. Natl. Acad. Sci. U.S.A. 104, 12488-12493 (2007).
14. J. Duan, J. Mu, M. A. Thera, D. Joy, S. L. Kosakovsky Pond, D. Diemert, C. Long, H. Zhou, K. Miura, A. Ouattara, A. Dolo, O. Doumbo, X. Z. Su, L. Miller, Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design. Proc. Natl. Acad. Sci. U.S.A. 105, 7857-7862 (2008).
15. O. J. Akpogheneta, N. O. Duah, K. K. Tetteh, S. Dunyo, D. E. Lanar, M. Pinder, D. J. Conway, Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect. Immun. 76, 1748-1755 (2008).
16. S. M. Kinyanjui, D. J. Conway, D. E. Lanar, K. Marsh, IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar. J. 6, 82 (2007).
17. D. Coulibaly, D. A. Diallo, M. A. Thera, A. Dicko, A. B. Guindo, A. K. Koné, Y. Cissoko, S. Coulibaly, A. Djimdé, K. Lyke, O. K. Doumbo, C. V. Plowe, Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am. J. Trop. Med. Hyg. 67, 604-610 (2002).
18. L. Breiman, Random forests. Mach. Learn. 45, 5-32 (2001).
19. D. P. Eisen, V. M. Marshall, H. Billman-Jacobe, R. L. Coppel, A Plasmodium falciparum apical membrane antigen-1 (AMA-1) gene apparently generated by intragenic recombination. Mol. Biochem. Parasitol. 100, 243-246 (1999).
20. S. Garg, M. T. Alam, M. K. Das, V. Dev, A. Kumar, A. P. Dash, Y. D. Sharma, Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Malar. J. 6, 154 (2007).
21. C. H. Kocken, D. L. Narum, A. Massougbodji, B. Ayivi, M. A. Dubbeld, A. van derWel, D. J. Conway, A. Sanni, A. W. Thomas, Molecular characterisation of Plasmodium reichenowi apicalmembrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol. Biochem. Parasitol. 109, 147-156 (2000).
22. V. M. Marshall, L. Zhang, R. F. Anders, R. L. Coppel, Diversity of the vaccine candidate AMA- 1 of Plasmodium falciparum. Mol. Biochem. Parasitol. 77, 109-113 (1996).
23. R. L. Ord, A. Tami, C. J. Sutherland, ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One 3, e3366 (2008).
24. M. G. Peterson, V. M. Marshall, J. A. Smythe, P. E. Crewther, A. Lew, A. Silva, R. F. Anders, D. J. Kemp, Integral membrane protein located in the apical complex of Plasmodium falciparum . Mol. Cell. Biol. 9, 3151-3154 (1989).
25. S. D. Polley, W. Chokejindachai, D. J. Conway, Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 165, 555-561 (2003).
26. V. Rajesh, V. K. Singamsetti, S. Vidya, M. Gowrishankar, M. Elamaran, J. Tripathi, N. B. Radhika, D. Kochar, A. Ranjan, S. K. Roy, A. Das, Plasmodium falciparum: Genetic polymorphism in apical membrane antigen-1 gene from Indian isolates. Exp. Parasitol. 119, 144-151 (2008).
27. J. K. Pritchard, X. Wen, D. Falush, Documentation for Structure Software, Version 2.2 (University of Chicago, Chicago, 2007).
28. A. M. Coley, A. Gupta, V. J. Murphy, T. Bai, H. Kim, M. Foley, R. F. Anders, A. H. Batchelor, Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog. 3, 1308-1319 (2007).
29. M. A. Thera, Randomized, controlled, dose escalation phase 1 clinical trial to evaluate the safety and immunogenicity of Walter Reed Army Institute of Research's AMA-1 malaria vaccine (FMP 2.1) adjuvanted in GSKBio's AS02A vs. rabies vaccine in 1-6 year old children in Bandiagara, Mali. Am. J. Trop. Med. Hyg. 77S, 144 (2007).
30. U. D'Alessandro, A. Leach, C. J. Drakeley, S. Bennett, B. O. Olaleye, G. W. Fegan, M. Jawara, P. Langerock, M. O. George, G. A. T. Targett, B. M. Greenwood, Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346, 462-467 (1995).
31. M. V. Valero, L. R. Amador, C. Galindo, J. Figueroa, M. S. Bello, L. A. Murillo, A. L. Mora, G. Patarroyo, C. L. Rocha, M. Rojas, J. J. Aponte, L. E. Sarmiento, D. M. Lozada, C. G. Coronell, N. M. Ortega, J. E. Rosas, M. E. Patarroyo, P. L. Alonso, Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705-710 (1993).
32. E. J. Remarque, B. W. Faber, C. H. Kocken, A. W. Thomas, A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76, 2660-2670 (2008).
33. S. L. Takala, D. Coulibaly, M. A. Thera, A. Dicko, D. L. Smith, A. B. Guindo, A. K. Kone, K. Traore, A. Ouattara, A. A. Djimde, P. S. Sehdev, K. E. Lyke, D. A. Diallo, O. K. Doumbo, C. V. Plowe, Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 4, e93 (2007).
34. C. R. Collins, C. Withers-Martinez, G. A. Bentley, A. H. Batchelor, A. W. Thomas, M. J. Blackman, Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J. Biol. Chem. 282, 7431-7441 (2007).
35. R. Chaudhuri, S. Ahmed, F. A. Ansari, H. V. Singh, S. Ramachandran, MalVac: Database of malarial vaccine candidates. Malar. J. 7, 184 (2008).
36. B. N. Kanoi, T. G. Egwang, New concepts in vaccine development in malaria. Curr. Opin. Infect. Dis. 20, 311-316 (2007).
37. M. Scarselli, M. M. Giuliani, J. Adu-Bobie, M. Pizza, R. Rappuoli, The impact of genomics on vaccine design. Trends Biotechnol. 23, 84-91 (2005).
38. T. C. Luke, S. L. Hoffman, Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003).
39. D. Coulibaly, D. A. Diallo, M. A. Thera, A. Dicko, A. B. Guindo, A. K. Koné, Y. Cissoko, S. Coulibaly, A. Djimdé, K. Lyke, O. K. Doumbo, C. V. Plowe, Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am. J. Trop. Med. Hyg. 67, 604-610 (2002).
40. K. E. Lyke, A. Dicko, A. Kone, D. Coulibaly, A. Guindo, Y. Cissoko, K. Traoré, C. V. Plowe, O. K. Doumbo, Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine 22, 3169-3174 (2004).
41. M. A. Thera, O. K. Doumbo, D. Coulibaly, D. A. Diallo, I. Sagara, A. Dicko, D. J. Diemert, D. G. Heppner Jr., V. A. Stewart, E. Angov, L. Soisson, A. Leach, K. Tucker, K. E. Lyke, C. V. Plowe; Mali FMP1 Working Group, Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: Results of a phase I randomized trial. PLoS Clin. Trials 1, e34 (2006).
42. S. L. Takala, D. Coulibaly, M. A. Thera, A. Dicko, D. L. Smith, A. B. Guindo, A. K. Kone, K. Traore, A. Ouattara, A. A. Djimde, P. S. Sehdev, K. E. Lyke, D. A. Diallo, O. K. Doumbo, C. V. Plowe, Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 4, e93 (2007).
43. A. Cortés, M. Mellombo, I. Mueller, A. Benet, J. C. Reeder, R. F. Anders, Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect. Immun. 71, 1416-1426 (2003).
44. T. A. Hall, BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids Symp. Ser. 41, 95-98 (1999).
45. J. P. Huelsenbeck, P. Andolfatto, Inference of population structure under a Dirichlet process model. Genetics 175, 1787-1802 (2007).
46. J. K. Pritchard, M. Stephens, P. Donnelly, Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000).
47. J. Pella, M. Masuda, The Gibbs and split-merge sampler for population mixture analysis from genetic data with incomplete baselines. Can. J. Fish. Aquat. Sci. 63, 576-596 (2006).
48. S. Dutta, S. Y. Lee, A. H. Batchelor, D. E. Lanar, Structural basis of antigenic escape of a malaria vaccine candidate. Proc. Natl. Acad. Sci. U.S.A. 104, 12488-12493 (2007).
49. A. Liaw, M. Wiener, Classification and regression by randomForest. R News 2 , 18-22 (2002).
50. R. Ihaka, R. Gentleman, R: A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299-314 (1996).
51. R Development Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2008).
52. M. R. Segal, M. P. Cummings, A. E. Hubbard, Relating amino acid sequence to phenotype: Analysis of peptide-binding data. Biometrics 57, 632-642 (2001).
53. M. P. Cummings, M. R. Segal, Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis. BMC Bioinformatics 5, 137 (2004).
54. M. P. Cummings, D. S. Myers, Simple statistical models predict C-to-U edited sites in plant mitochondrial RNA. BMC Bioinformatics 5, 132 (2004)
55. Acknowledgments: We thank the population and the regional and district health authorities of Bandiagara, Mali for their continued support and the Bandiagara Malaria Project staff and managers for their dedication.